← Back

Viemed Healthcare Inc

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

Price · split & dividend adjusted
News & notes moving VMD
VMD

Viemed Healthcare to report Q2 earnings before market open on August 4th

Viemed Healthcare is scheduled to announce its second-quarter earnings results on Tuesday, August 4th, before the market opens. The consensus earnings per share estimate stands at $0.12, while the consensus revenue estimate is $78 million. Over the past year, the company has beaten EPS estimates 75% of the time and revenue estimates 75% of the time.
Seeking Alpha·23dRead more ▾
Biotech & Genomic Medicine

Biotech Stocks Hit 52-Week Highs on Clinical Results and New Initiatives

Several biotech stocks reached 52-week highs on July 14, 2026, driven by positive clinical data and new program launches. Hemab Therapeutics hit $42.03 after reporting encouraging Phase 2 results for its Von Willebrand's disease candidate HMB-002 and unveiling a new drug candidate, HMB-003, for heavy menstrual bleeding. Alamar Biosciences touched $29.43 following a partnership with U.S. research universities to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer's biomarker discovery. Progyny rose over 4% to $32, with the company projecting full-year 2026 revenue between $1.365 billion and $1.405 billion, a 5.9% to 9% increase. 10x Genomics closed at a 52-week high of $43.98 after recent collaborations, including a bladder cancer diagnostic project with Cleveland Clinic, and expects 2026 revenue of $600 million to $625 million. Viemed Healthcare peaked at $12.61, forecasting net revenues of $312 million to $320 million for 2026.
RTTNews·44dRead more ▾